Genetic markers found to signal blood cancers years before symptoms
Long‑term studies of chronic blood cancers have identified genetic alterations that can appear decades before disease progression becomes clinically evident. Researchers at the Wellcome Sanger Institute and collaborators published the findings in *Cancer Discovery*, noting that in the United Kingdom roughly 40,000 people live with myeloproliferative neoplasms (MPNs) and about 4,000 new cases are diagnosed each year. Most MPNs carry mutations in the JAK2, CALR or MPL genes, though around 10 % of patients lack these common changes.
In a separate international investigation, scientists discovered a key genetic change that clarifies how leukemia develops in children with Down syndrome. The work shows that myeloid leukemia in these children often arises from transient abnormal myelopoiesis present in a subset of newborns with the syndrome. The finding could enable earlier detection and more targeted monitoring of high‑risk children, paving the way for less aggressive, biology‑driven treatments.
Entities: CALR gene · Down syndrome · JAK2 gene · MPL gene · Wellcome Sanger Institute
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] Most myeloproliferative neoplasms are associated with mutations in the JAK2, CALR or MPL genes.
- [● 2 SOURCES] The discovery could enable earlier detection and more precise monitoring of high‑risk children with Down syndrome.
- [● 2 SOURCES] A specific genetic change has been identified that explains how leukemia develops in children with Down syndrome.
- [○ 1 SOURCE] Around 10 % of myeloproliferative neoplasm patients lack the common JAK2, CALR or MPL genetic alterations.
- [○ 1 SOURCE] The study was led by researchers at the Wellcome Sanger Institute.
- [● 2 SOURCES] Leukemia in children with Down syndrome often originates from transient abnormal myelopoiesis present in some newborns with the syndrome.
- [○ 1 SOURCE] Genetic changes can appear years before blood cancer symptoms become evident. (Study published in Cancer Discovery)
- [○ 1 SOURCE] In the United Kingdom about 40,000 people live with myeloproliferative neoplasms and around 4,000 new cases are diagnosed each year.